Anavex Life Sciences Yönetim

Yönetim kriter kontrolleri 3/4

Anavex Life Sciences CEO'su Chris Missling, Jul2013 tarihinde atandı, in görev süresi 11.33 yıldır. in toplam yıllık tazminatı $ 3.89M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18% maaş ve 82% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.47% ine doğrudan sahiptir ve bu hisseler $ 11.30M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 10.5 yıldır.

Anahtar bilgiler

Chris Missling

İcra Kurulu Başkanı

US$3.9m

Toplam tazminat

CEO maaş yüzdesi	18.0%
CEO görev süresi	11.3yrs
CEO sahipliği	1.5%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	10.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Chris Missling'un ücretlendirmesi Anavex Life Sciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$42m
Mar 31 2024	n/a	n/a	-US$41m
Dec 31 2023	n/a	n/a	-US$43m
Sep 30 2023	US$4m	US$700k	-US$48m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$53m
Dec 31 2022	n/a	n/a	-US$50m
Sep 30 2022	US$7m	US$586k	-US$48m
Jun 30 2022	n/a	n/a	-US$45m
Mar 31 2022	n/a	n/a	-US$43m
Dec 31 2021	n/a	n/a	-US$41m
Sep 30 2021	US$9m	US$550k	-US$38m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$28m
Dec 31 2020	n/a	n/a	-US$28m
Sep 30 2020	US$2m	US$550k	-US$26m
Jun 30 2020	n/a	n/a	-US$26m
Mar 31 2020	n/a	n/a	-US$26m
Dec 31 2019	n/a	n/a	-US$26m
Sep 30 2019	US$3m	US$513k	-US$26m
Jun 30 2019	n/a	n/a	-US$26m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	n/a	n/a	-US$20m
Sep 30 2018	US$3m	US$500k	-US$17m

Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 3.89M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.45M ).

Tazminat ve Kazançlar: Chris 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Chris Missling (58 yo)

11.3yrs

Görev süresi

US$3,894,453

Tazminat

Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and also serves as its Director an...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Missling	President	11.3yrs	US$3.89m	1.47% $ 11.3m
Sandra Boenisch	Principal Financial Officer & Treasurer	9.1yrs	US$501.06k	0.027% $ 207.5k
Walter Kaufmann	Chief Scientific Officer	2.8yrs	Veri yok	Veri yok
Clint Tomlinson	VP of Corporate	no data	Veri yok	Veri yok
Adebayo Laniyonu	Senior Vice President of Nonclinical Development	3.5yrs	Veri yok	Veri yok
Edward Hammond	Chief Medical Officer	2.8yrs	Veri yok	Veri yok
Kun Jin	Head of Biostatistics	1.7yrs	Veri yok	Veri yok
David Goldberger	Senior Vice President of Regulatory Affairs	less than a year	Veri yok	Veri yok
Terrie Kellmeyer	Senior Vice President of Clinical Development	less than a year	Veri yok	Veri yok
Juan Carlos Lopez-Talavera	Senior VP & Head of Research and Development	less than a year	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 0HFR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Missling	President	11.3yrs	US$3.89m	1.47% $ 11.3m
Jiong Ma	Independent Chairman	3.5yrs	US$349.54k	Veri yok
Jacqueline A. French	Member of the Scientific Advisory Board	9.7yrs	Veri yok	Veri yok
Paul Aisen	Member of the Scientific Advisory Board	13.8yrs	Veri yok	Veri yok
John Harrison	Member of the Scientific Advisory Board	10.9yrs	Veri yok	Veri yok
Ottavio Arancio	Member of the Scientific Advisory Board	11yrs	Veri yok	Veri yok
Tangui Maurice	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Athanasios Skarpelos	Independent Director	11.8yrs	US$341.54k	1.54% $ 11.8m
Norman Relkin	Member of the Scientific Advisory Board	10.5yrs	Veri yok	Veri yok
Corinne Lasmézas	Member of the Scientific Advisory Board	9.7yrs	Veri yok	Veri yok
Steffen Thomas	Independent Director	9.4yrs	US$341.54k	0.0059% $ 45.2k
Claus van der Velden	Lead Independent Director	6.7yrs	US$357.54k	Veri yok

10.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0HFR 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.5 yıldır).

Anavex Life Sciences Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Anavex Life Sciences Corp Announces Management Appointments

Anavex Life Sciences Corp., Annual General Meeting, Jun 18, 2024

Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs

Anavex Life Sciences Corp. Announces the Appointment of Timo Grimmer, Md, to Its Scientific Advisory Board

Insufficient new directors

Recent updates

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

New major risk - Share price stability

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

Anavex Life Sciences Corp Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

New major risk - Share price stability

Anavex Life Sciences Corp. to Report Q3, 2024 Results on Aug 06, 2024

Forecast breakeven date moved forward to 2025

Anavex Life Sciences Corp. Presents comprehensive results from the Phase IIb/III study of Blarcamesine at Alzheimer's Association Conference

Insufficient new directors

Anavex Life Sciences Corp Announces Management Appointments

Anavex Life Sciences Corp., Annual General Meeting, Jun 18, 2024

Anavex Life Sciences Corp. to Report Q2, 2024 Results on May 09, 2024

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®?3-71 in Schizophrenia

Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation

No longer forecast to breakeven

Anavex Life Sciences Corp. to Report Q1, 2024 Results on Feb 07, 2024

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia

Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome

Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease

New major risk - Revenue and earnings growth

Forecast to breakeven in 2025

Anavex Life Sciences Corp. to Report Fiscal Year 2023 Results on Nov 27, 2023

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency

Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs

Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease

Anavex Life Sciences Corp. Announces Phase 2b/3 Trial of Blarcamesine (ANAVEX 2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

Anavex Life Sciences Reports Publication of ANAVEX®?3-71 in Clinical Journal Confirming ANAVEX®? 3-71 Clinical Cardiovascular Safety

Anavex Life Sciences Corp. to Report Q3, 2023 Results on Aug 08, 2023

Anavex Life Sciences Corp. Announces Long-Term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX(R)2-73 (blarcamesine) for Rett Syndrome

Anavex Life Sciences Corp.'s ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

Anavex Life Sciences Corp. Announces Completion of Anavex((R))2-73 (Blarcamesine) Excellence Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp. Announces Exceeding of Enrollment Target for the ANAVEX(R)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp. to Report Q1, 2023 Results on Feb 07, 2023

Anavex Life Sciences Corp. Announces the Appointment of Timo Grimmer, Md, to Its Scientific Advisory Board

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Anavex Life Sciences Corp. to Report Q4, 2022 Results on Nov 28, 2022

Insufficient new directors

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2B/3 Data of Oral Anavex®2-73 (Blarcamesine) for Early Alzheimer’s Disease At the Upcoming Clinical Trials on Alzheimer’S Disease (Ctad) Congress 2022

Forecast to breakeven in 2025

Anavex Life Sciences Corp. Reports New Publication in Medical Journal Highlighting the Relevance of Sigmar1 Activation to Compensate for Early Alzheimer's Disease

Anavex Life Sciences Corp. to Report Q3, 2022 Results on Aug 09, 2022

Anavex Life Sciences Corp. to Report Q2, 2022 Results on May 10, 2022

Insufficient new directors

Anavex Life Sciences Corp., Annual General Meeting, May 24, 2022

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome

Anavex Life Sciences Corp. to Report Q1, 2022 Results on Feb 09, 2022

Anavex Life Sciences Corp. Reports Positive Top-Line Results from the Phase 3 Randomized, Double-Blind, Placebo-Controlled AVATAR trial of ANAVEX®2-73

Anavex Life Sciences Corp. Reports Positive Results from Phase 1 Clinical Trial of ANAVEX3-71

Forecast to breakeven in 2024

No longer forecast to breakeven

No longer forecast to breakeven

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)

Anavex Life Sciences Announces Anavex 2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome

Anavex Life Sciences Corp. Reports New Publication in Medical Journal Elucidating the Mechanism of Anavex®2-73 (Blarcamesine) and Anavex®3-71 (AF710B) Related to the Treatment of Alzheimer's Disease

Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (Blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease

Independent Director has left the company

Forecast breakeven pushed back to 2024

Forecast breakeven pushed back to 2024

Anavex Life Sciences Reports Anavex®2-73 (Blarcamesine) Featured as Disease-Modifying Small Molecule in Phase 3 Clinical Trials

Anavex Life Sciences Corp. to Report Q1, 2021 Results on Feb 11, 2021

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş